Purpose: Protecting patients from the acute and/or chronic toxicity of antineoplastic therapy has become a major concern of oncology centers around the world. Glutamine has been used as a multisystemic protective agent to minimize the side effects arising from the treatment of childhood cancers. In this study, the effect of intravenous glutamine supplementation was investigated in children receiving chemotherapy for non-Hodgkin lymphoma.
Results: There were no significant differences in the hematological parameters between the 2 groups. The requirements for red blood cells and platelets during the chemotherapy courses were similar in both groups (P = 0.64 and 0.40, respectively). Patients supplemented with glutamine developed mucositis in 21 of 30 courses (70%) and patients without glutamine supplements developed mucositis in 23 of 31 courses (74%). The mean duration of mucositis and the mean mucositis score in each course were similar between the 2 groups. In addition, gastrointestinal system and hepatic toxicity did not differ between groups. The mean duration of febrile neutropenia and the length of hospitalization were also similar in both groups (P = 0.09 and 0.13, respectively).
Conclusions: Parenteral glutamine supplementation has no effect on mucositis, fever and febrile neutropenia, length of hospitalization, red blood cell, and platelet requirements, and hematological, gastrointestinal, and hepatic toxicities in children receiving severe chemotherapy.
Key Words: glutamine, chemotherapy, non-Hodgkin lymphoma (J Pediatr Hematol Oncol 2013;35:371-376) P rotecting patients from the acute and/or chronic toxicity of antineoplastic therapy has become a major concern of oncology centers around the world. Chemotherapeutic agents are not specific to neoplastic cells, and therefore, a broad range of normal tissues, primarily including the bone marrow, the gastrointestinal epithelium, the kidneys and bladder, the lungs, the nervous, and the cardiovascular systems, may be adversely affected. Thus, the quality of life of patients may be impaired and tumor control may be reduced because of the inability to deliver the adequate doses required to eliminate the cancer. Chemoprotectants have been developed to ameliorate the toxicity associated with cytotoxic agents, and chemoprotectants function by providing site-specific protection for normal tissues, without compromising antitumor efficacy. 1, 2 Glutamine (Gln) has anabolic effects in stressed patients and, among many key metabolic functions, is used as a major substrate by cells of the gastrointestinal epithelium and the immune system. 3 Glutamine is frequently used by rapidly dividing cells, such as enterocytes, lymphocytes, and fibroblasts, as a nitrogen source, and in vitro studies have indicated that cancer cells preferentially metabolize glutamine. In patients with cancer, marked Gln depletion develops over time, and cancer cachexia is marked by the massive depletion of skeletal muscle Gln. Glutamine depletion can negatively affect the function of host tissues that are dependent upon adequate stores of Gln for optimal functioning, such as the intestinal epithelial cells and lymphocytes. Furthermore, the extent of normal tissue damage from radiation or chemotherapy may be influenced by the presence of adequate tissue Gln stores. This association supports a possible therapeutic role for Gln in the prevention of host normal tissue toxicity during cancer treatment. 4 Many chemotherapeutic drugs, especially anthracyclines, actinomycin, and high-dose methotrexate, result in both structural and functional injuries to the gastrointestinal tract, causing mucositis that may be severe enough to prevent the adequate oral intake. 5 Although animal data on the effects of Gln supplementation are extensive, clinical studies are still quite limited. 6, 7 The administration of enteral or parenteral Gln has been shown to be safe and potentially efficacious in some patient groups undergoing intensive treatment for cancer. Studies have indicated that adjunctive Gln treatment may improve nitrogen retention, decrease clinical infection and length of hospital stay, and reduce the incidence and severity of mucositis after high-dose chemotherapy and bone marrow transplantation. [8] [9] [10] In this study, we investigated the effect of intravenous Gln supplementation on hematological parameters, mucositis, and fever duration in children receiving chemotherapy for non-Hodgkin lymphoma.
PATIENTS AND METHODS
This prospective study was carried out in a group of patients who were homogenous in terms of diagnosis and treatment. Children with B-cell non-Hodgkin lymphoma, who were followed by the Department of Pediatric Oncology between April 2008 and June 2010, were enrolled in the study. The median age of the patients was 72 months, with a range from 48 to 120 months. Table 1 summarizes the demographics, stages, and treatment groups of the patients. All patients were treated using the NHL-BFM 90 protocol, which consisted of 5 days of consecutive AA and BB courses with an interval of 15 days ( Table 2 ; Fig. 1 ). The patients receiving the AA courses with Gln supplementation received the BB courses without Gln supplementation. In contrast, the patients receiving the AA courses without Gln supplementation received the BB courses with Gln supplementation. All patients were used as their own controls. Group A consisted of the courses with Gln supplementation (15 AA and 15 BB courses) and group B (16 AA and 15 BB courses) consisted of the courses without Gln supplementation.
Glutamine (Dipeptiven; Fresenius Kabi, Graz, Australia) was given intravenously beginning on the first day of the chemotherapy regimen and continuing for 7 days. A dose of 0.4 g/kg/d was used, in accordance with previous studies in children, 9 and was infused within a period of 4 hours. Patients were monitored before, during, and after the infusion of Gln for any adverse effects. Chemotherapy was administered 30 minutes after Gln cessation. Vital signs, including blood pressure, heart rate, and respiratory rate, were recorded during the 7 days of Gln treatment. Renal function tests were evaluated on the first, fifth, and 10th days of therapy.
Granulocyte colony-stimulating factor was administered subcutaneously at a dose of 5 mcg/kg/d beginning 24 hours after the chemotherapy courses were completed and was continued for 3 consecutive days until the absolute neutrophil count reached 1000 cells/mm 3 . Patients were evaluated on the first, fifth (the beginning and the end of the courses), and 10th days of each chemotherapy courses to determine the hepatic, gastrointestinal, mucosal, and hematological toxicities. In clinical practice, the nadir blood counts and manifestations of other toxicities are mostly observed at about day 10. Mucositis and liver function tests were assessed using the WHO criteria for grading of oral mucositis and hepatic toxicity. 5, 11 The number of days in which diarrhea was observed and the number of vomiting episodes per course were recorded. In addition, erythrocyte and platelet transfusion requirements of the patients, and initiation time and duration of febrile neutropenia were recorded.
Neutropenia was defined as an absolute neutrophil count of <500 cells/mm 3 . Fever was defined as either a single axillary temperature of at least 38.51C, or axillary temperatures exceeding 38.01C for Z1 hour or twice within a 12-hour period. 12 Statistical analyses were performed with SPSS (Statistical Package for Social Sciences) 15.0 for Windows software. The Pearson w 2 (or Fisher exact test) and MannWhitney U test were used to evaluate the data, and P < 0.05 was accepted as the threshold for statistical significance. This study was approved by the Institutional Ethics Committee at the Atatu¨rk University, Faculty of Medicine.
RESULTS
Sixty-one courses of treatment, which were administered to 12 patients, 2 girls and 10 boys, were evaluated. Thirty courses were given in combination with Gln (group A), and 31 courses were administered without Gln (group B). Sixty-eight courses of chemotherapy were originally administrated; however, 2 patients were lost to follow-up after 1 and 2 cycles of chemotherapy, and thus, only 61 courses of treatment were evaluated. There were no differences regarding age, sex, stage of disease, and number of chemotherapy courses between groups A and B. In addition, there were no apparent cardiac, nephrological, neurological, respiratory system toxicities related to the use of glutamine in either group. Analysis of hematological toxicity showed no significant differences in the hemoglobin levels and the leukocyte and platelet counts between the 2 groups. The mean duration of granulocyte colony-stimulating factor administration was also similar in both groups (P = 0.74; Table 3 ).
The patients' requirements for red blood cells (RBC) and platelets during the chemotherapy courses were similar in both groups. The mean packaged RBC transfusion number was 1.00 ± 1.20 per course with Gln, whereas it was 0.87 ± 0.95 per course without Gln. This difference was statistically insignificant (P = 0.64). There was no difference in the mean platelet transfusion number per course between the groups (P = 0.40), as shown in Table 4 .
Mucositis developed in 21 of 30 courses (70%) with Gln (grade 1: 6, grade 2: 3, grade 3: 8, grade 4: 4) and in 23 of 31 courses (74%) without Gln (grade 1: 7, grade 2: 10, grade 3: 4, grade 4: 2; P = 0.18). The mean duration of mucositis in each course was similar between the 2 groups (P = 0.21; Table 4 ). The mean mucositis score was 1.73 ± 1.48 in group A and 1.52 ± 1.21 in group B (P = 0.53).
We found that the patients in group B experienced fever for fewer days (2.65 ± 2.93) than the patients in group A (4.53 ± 5.73). However, this difference was statistically insignificant (P = 0.11). The mean duration of febrile neutropenia and the length of hospitalization were also similar in both groups (P = 0.09 and 0.13, respectively; Table 4 ).
Gastrointestinal system and hepatic toxicity was similar between the 2 groups. The mean AST and ALT values of patients were compared and were found to be similar (P = 0.19). Patients developed hepatotoxicity in 14 of 30 courses (47%) with Gln (grade 1: 4, grade 2: 5, grade 3: 5, grade 4: 0) and in 14 of 31 courses (45%) without Gln (grade 1: 4, grade 2: 8, grade 3: 2, grade 4: 0; P = 0.57). The mean liver function test scores were 0.96 ± 1.18 in group A and 0.83 ± 1.03 in group B (P = 0.65). The frequency and duration of diarrhea and vomiting was also comparable between the 2 groups. Diarrhea was observed in 13 courses with Gln (43%) and 12 courses without Gln (39%; P = 0.13), whereas vomiting was observed in 11 courses with Gln (37%) and 10 (32%) courses without Gln (P = 0.76; Table 5 ).
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DISCUSSION
An increasing number of clinical investigations have focused on the efficacy of Gln supplementation following catabolic conditions, such as chemotherapy, sepsis, and trauma. Published studies have indicated that enteral and parenteral Gln administration is well tolerated and is potentially efficacious in intensive care patients and in patients who have received high-dose chemotherapy or bone marrow transplantation (BMT) for cancer treatment. 4, 10, [13] [14] [15] Most of the studies in the literature have been carried out in adult patients and in patients who have undergone hematopoietic stem cell transplantation. The published studies have not yielded consistent results, however, which may be because of differences in the patient populations and therapeutic procedures (Table 6) . In this study, we evaluated Gln efficacy in children with non-Hodgkin lymphoma, which necessitates an intensive chemotherapy regimen, often resulting in gastrointestinal toxicity. To ensure homogeneity in our patient group, we only accepted patients with non-Hodgkin lymphoma for treatment.
Ziegler et al 16 performed a double blind, randomizedcontrolled clinical trial in adult patients receiving allogeneic BMTs for hematological malignancies. The authors showed that patients receiving glutamine-supplemented parenteral nutrition after BMT had improved nitrogen balance, diminished incidence of clinical infection, lower rates of microbial colonization, and shortened hospital stays, compared with patients receiving standard parenteral nutrition. These effects occurred despite no differences between groups regarding the incidence of fever, antibiotic requirements, or the time required for neutrophil engraftment. However, using a similar protocol to Ziegler et al, 16 Schloerb and Amare 17 demonstrated that in patients with hematological malignancies or solid tumors who had undergone allogeneic or autologous BMTs, total parenteral nutrition supplemented with L-glutamine did not have discernible effects on the incidence of positive bacterial cultures, clinical infections, and patient mortality. However, they showed that patients receiving Gln stayed in the hospital for significantly shorter lengths of time. Benes et al 21 evaluated 40 adult 20 compared 58 autologous and allogeneic BMT patients receiving daily doses of 30 g of oral glutamine or placebo. The authors did not observe any statistically significant differences in the length of hospitalization, the number of days and highest grade of mucositis, and the quantity and number of days of diarrhea. The conflicting results that have been reported in the studies mentioned above may be because of differences in the study populations (hematological malignancies or solid tumors), the procedures (autologous or allogeneic BMT), the conditioning regimens used in BMT, and the daily dose and duration of glutamine supplementation. We found that glutamine supplementation did not affect the length of hospitalization of patients, the severity of mucositis, and the duration of fever, febrile neutropenia, and diarrhea. However, as our study population (children vs. adult), chemotherapy regimen (intensive chemotherapy vs. conditioning regimens for BMT), and dose and duration of glutamine supplementation differed from previous studies, our results are not directly comparable with previous reports.
Van Zaanen et al 18 performed a prospective, double blind, placebo-controlled pilot study in unselected hematological patients with intensive chemotherapy. The authors compared 2 groups receiving total parenteral nutrition with or without 40 g of glutamine supplementation, until the neutrophil count of patients was >0.5 Â10 9 cells/L. They found no significant differences in neutropenic period, fever, extra antibiotics, toxicity scores for mucositis, performance status, and diarrhea. Although the findings from Van Zaanen and colleagues were compatible with the results of our study, their study was carried out on adult patients.
The data in pediatric populations are more limited. Aquino et al 22 reported that oral glutamine supplementation reduced the severity of mucositis and the requirement of total parenteral nutrition and intravenous narcotics in children undergoing hematopoietic stem cell transplantation. Kuskonmaz et al 9 showed that 0.4 g/kg/d parenteral Gln supplementation, starting 9 days before transplantation and continuing for 21 days after transplantation, reduced the duration of fever. However, the supplementation had no effect on the incidence of fever or infection after the hematopoietic stem cell transplantation in pediatric patients. Uderzo et al 24 studied a larger group and reported that glutamine-enriched TPN did not affect mucositis and clinical outcomes. The authors used the same protocol for glutamine as previous studies but did not detect any differences in the duration of fever and in the severity of mucositis. On the contrary, there was a trend toward an increased rate of some side effects, such as the duration of fever in the Gln group.
Anderson et al 19 evaluated oral glutamine supplementation during and after chemotherapy in a group of patients, including children and adults. The authors found that glutamine significantly reduced both the duration and the severity of chemotherapy-associated stomatitis. Okur et al 23 showed that in children with various solid tumors, oral Gln supplementation of 4 g/m 2 /d for 5 days during the chemotherapy course significantly improved some immunologic and nutritional parameters and reduced the necessity for antibiotics. Specifically, it was reported that the white blood cell count of patients in the Gln supplemented group decreased significantly. However, the hemoglobin values of patients in the control group decreased on the fifth day, compared with the first day. In our present study, we found that parenteral supplemented Gln did not affect the white blood cell and platelet counts and hemoglobin values on the fifth and 10th day of treatment and did not alter the patients' requirements for RBC and platelet transfusions.
In conclusion, our study suggests that parenteral Gln supplementation may have no beneficial effects on mucositis, fever and febrile neutropenia, length of hospitalization, RBC and platelet requirements, and hematological, gastrointestinal, and hepatic toxicities in children receiving intensive chemotherapy. However, given the limitation of the small number of patients that were included in our study, our findings should be confirmed in additional double-blinded, randomized studies with larger group of patients.
